International Medicine and Health Guidance News ›› 2025, Vol. 31 ›› Issue (16): 2761-2765.DOI: 10.3760/cma.j.cn441417-20241223-16024
• Clinical Research • Previous Articles Next Articles
Predictive value of CT muscle characteristic indicators for chemotherapy sensitivity in patients with rectal cancer
Chen Kun, Liu Yaliang, Qin Shumin, Sheng Jiexin, Yang Lin, Hao Yang
Department of Medical Imaging, Hanzhong City Center Hospital, Hanzhong 723000, China
Received:
2024-12-23
Online:
2025-08-15
Published:
2025-08-28
Contact:
Hao Yang, Email: haoyang112@163.com
Supported by:
Shaanxi Provincial Health Research Fund (2022B011)
CT肌肉特征指标对结直肠癌患者化疗敏感程度的预测价值
陈堃 刘亚良 秦书敏 盛杰鑫 杨琳 郝阳
汉中市中心医院医学影像科,汉中 723000
通讯作者:
郝阳,Email:haoyang112@163.com
基金资助:
陕西省卫生健康科研基金(2022B011)
Chen Kun, Liu Yaliang, Qin Shumin, Sheng Jiexin, Yang Lin, Hao Yang.
Predictive value of CT muscle characteristic indicators for chemotherapy sensitivity in patients with rectal cancer [J]. International Medicine and Health Guidance News, 2025, 31(16): 2761-2765.
陈堃 刘亚良 秦书敏 盛杰鑫 杨琳 郝阳.
CT肌肉特征指标对结直肠癌患者化疗敏感程度的预测价值 [J]. 国际医药卫生导报, 2025, 31(16): 2761-2765.
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.imhgn.com/EN/10.3760/cma.j.cn441417-20241223-16024
[1] Shin AE, Giancotti FG, Rustgi AK. Metastatic colorectal cancer: mechanisms and emerging therapeutics[J]. Trends Pharmacol Sci, 2023, 44(4):222-236. DOI:10.1016/j.tips.2023.01.003. [2] Derstine BA, Holcombe SA, Ross BE, et al. Optimal body size adjustment of L3 CT skeletal muscle area for sarcopenia assessment[J]. Sci Rep, 2021, 11(1):279. DOI:10.1038/s41598-020-79471-z. [3] Dy GK, Hobday TJ, Nelson G, et al. Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144[J]. Clin Colorectal Cancer, 2009, 8(2):88-93. [4] Jiang N, Zhang J, Cheng S, et al. The role of standardized phase angle in the assessment of nutritional status and clinical outcomes in cancer patients: a systematic review of the literature[J]. Nutrients, 2022, 15(1):50. DOI:10.3390/nu15010050. [5] Gray C, MacGillivray TJ, Eeley C, et al. Magnetic resonance imaging with k-means clustering objectively measures whole muscle volume compartments in sarcopenia/cancer cachexia[J]. Clin Nutr, 2011, 30(1):106-111. DOI:10.1016/j.clnu.2010.07.012. [6] Erul E, Guven DC, Onur MR, et al. Role of sarcopenia on survival and treatment-related toxicity in head and neck cancer: a narrative review of current evidence and future perspectives[J]. Eur Arch Otorhinolaryngol, 2023, 280(8):3541-3556. DOI:10.1007/s00405-023-08014-9. [7] Martinez-Tapia C, Rougette K, Fossey-Diaz V, et al. Prevalence of four sarcopenia criteria in older patients with cancer, and their predictive value for 6-month mortality: the NutriAgeCancer national prospective cohort study[J]. Nutrients, 2023, 15(6):1508. DOI:10.3390/nu15061508. [8] Yamanouchi K, Murakami S, Sato A, et al. Integrated evaluation of inflammatory, nutritional, and sarcopenia markers to predict survival in metastatic breast cancer patients[J]. In Vivo, 2023, 37(2):811-817. DOI: 10.21873/invivo.13146. [9] Meyer HJ, Wienke A, Surov A. Sarcopenia as a prognostic marker for survival in gastric cancer patients undergoing palliative chemotherapy: a systematic review and meta-analysis [J]. Nutr Cancer, 2022, 74(10): 3518-3526. DOI: 10.1080/01635581.2022.2077387. [10] Dong D, Shi JY, Shang X, et al. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib: a retrospective analysis[J]. Medicine (Baltimore), 2022, 101(5):e28680. DOI: 10.1097/MD.0000000000028680. [11] Morse B, Jeong D, Ihnat G, et al. Pearls and pitfalls of response evaluation criteria in solid tumors (RECIST) v1.1 non-target lesion assessment [J]. Abdom Radiol (NY), 2019, 44(2): 766-774. DOI:10.1007/s00261-018-1752-4. [12] Mourtzakis M, Prado CM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care[J]. Appl Physiol Nutr Metab, 2008, 33(5):997-1006. DOI:10.1139/H08-075. [13] Von Geldern P, Salas C, Alvayay P, et al. Nutritional assessment by subjective methods versus computed tomography to predict survival in oncology patients[J]. Nutrition, 2021, 84:111006. DOI:10.1016/j.nut.2020.111006. [14] Benedek Z, Todor-Boér S, Kocsis L, et al. Psoas muscle index defined by computer tomography predicts the presence of postoperative complications in colorectal cancer surgery[J]. Medicina (Kaunas), 2021, 57(5):472. DOI:10.3390/medicina57050472. [15] Kroenke CH, Prado CM, Meyerhardt JA, et al. Muscle radiodensity and mortality in patients with colorectal cancer[J]. Cancer, 2018, 124(14):3008-3015. DOI:10.1002/cncr.31405. [16] Chen X, Xiang H, Tan L, et al. Psoriasis is associated with myosteatosis but not sarcopenia: a case-control study[J]. Front Med (Lausanne), 2021, 8:754932. DOI:10.3389/fmed.2021.754932. [17] Chen B, Zhang RN, Fan X, et al. Clinical diagnostic value of long non-coding RNAs in colorectal cancer: a systematic review and meta-analysis[J]. J Cancer, 2020, 11(18):5518-5526. DOI:10.7150/jca.46358. [18] 李德正,段红亮,吴云桦,等. ST6Gal1与结直肠癌患者临床病理特征及预后的相关性[J]. 国际医药卫生导报, 2024, 30(11):1882-1887. DOI:10.3760/cma.j.issn.1007-1245.2024.11.025. [19] Fukushima H, Koga F. Impact of sarcopenia in the management of urological cancer patients[J]. Expert Rev Anticancer Ther, 2017, 17(5):455-466. DOI:10.1080/14737140.2017.1301209[J]. [20] Fang P, Zhou J, Xiao X, et al. The prognostic value of sarcopenia in oesophageal cancer: a systematic review and meta-analysis[J]. J Cachexia Sarcopenia Muscle, 2023, 14(1):3-16. DOI:10.1002/jcsm.13126. [21] Fukushima H, Takemura K, Suzuki H, et al. Impact of sarcopenia as a prognostic biomarker of bladder cancer[J]. Int J Mol Sci, 2018, 19(10):2999. DOI:10.3390/ijms19102999. [22] Li Z, Yan G, Liu M, et al. Association of perioperative skeletal muscle index change with outcome in colorectal cancer patients [J]. J Cachexia Sarcopenia Muscle, 2024, 15(6):2519-2535. DOI: 10.1002/jcsm.13594. [23] Yokoi K, Watanabe A, Yokota K, et al. Low skeletal muscle radiodensity is a risk factor for adjuvant chemotherapy discontinuation in colorectal cancer[J]. Int J Clin Oncol, 2024, 29(3):276-285. DOI: 10.1007/s10147-023-02463-2. [24] Wang Y, Wang Y, Li G, et al. Associations of intermuscular adipose tissue and total muscle wasting score in PG-SGA with low muscle radiodensity and mass in nonmetastatic colorectal cancer: a two-center cohort study[J]. Front Nutr, 2022, 9:967902. DOI:10.3389/fnut.2022.967902. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||